Anti-HLA-G Biotin

Anti-HLA-G Biotin
Regulatory status
RUO
Antigen
HLA-G
Clone
5A6G7
Format
Biotin
Reactivity
Human
Variant
0.1 mg
1B-431-C100
In stock
286.00 USD

0.025 mg
1B-431-C025
Delivery 1 week
143.00 USD
Variant
0.1 mg
1B-431-C100
In stock
286.00 USD

0.025 mg
1B-431-C025
Delivery 1 week
143.00 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG1
Specificity
The mouse monoclonal antibody 5A6G7 was generated to a peptide corresponding to C-intron 4-encoded sequence. This antibody does not crossreact with the full-length HLA-G1 isoform and thus allows to distinguish between secreted HLA-G5 and HLA-G6 isoforms from shedded HLA-G1.
Application details
Flow cytometry: Recommended dilution: 1-4 μg/ml. Intracellular staining.
Reactivity
Human
Immunogen
C-terminal amino acid sequence (22-mer) of soluble HLA-G5 and HLA-G6 proteins coupled to ovalbumin.
Concentration
1 mg/ml
Preparation
Purified antibody is conjugated with biotin LC-NHS ester under optimum conditions and unconjugated antibody and free biotin are removed by size-exclusion chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Antigen description
Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.
Entrez Gene ID 3135
UniProt ID P17693
1B-431 FC
Flow cytometry analysis (intracellular staining) of HLA-G in HLA-G1 transfectants with anti-HLA-G (5A6G7) biotin / streptavidin-APC.

General references:

Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, Charpentier B, Carosella ED, Rouas-Freiss N. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol. 2003 39(4):587-94.
PubMed
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, LeDanff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 64(3):315-26.
PubMed
Lin A, Yan WH: Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front Immunol. 2018 Sep 27;9:2164.
PubMed
Hunt JS, Langat DK, McIntire RH, Morales PJ: The role of HLA-G in human pregnancy. Reprod Biol Endocrinol. 2006;4 Suppl 1(Suppl 1):S10.
PubMed
Xu HH, Yan WH, Lin A: The role of HLA-G in human papillomavirus infections and cervical carcinogenesis. Front Immunol. 2020 Jun 25;11:1349.
PubMed
Castelli EC, de Almeida BS, Muniz YC, Silva NS, Passos MR, Souza AS, Page AE, Dyble M, Smith D, Aguileta G, Bertranpetit J, Migliano AB, Duarte YA, Scliar MO, Wang J, Passos-Bueno MR, Naslavsky MS, Zatz M, Mendes CT, Donadi EA: HLA-G genetic diversity and evolutive aspects in worldwide populations. Sci Rep. 2021 Nov 29;11(1):23070.
PubMed
Curigliano G, Criscitiello C, Gelao L, Goldhirsch A: Molecular pathways: Human leukocyte antigen G (HLA-G). Clin Cancer Res. 2013 Oct 15;19(20):5564-71.
PubMed

Product specific references:

Poláková K, Železníková T, Russ G: HLA-G5 in the blood of leukemia patients and healthy individuals. Leuk Res. 2013 Feb;37(2):139-45.
PubMed
Rebmann V, Lemaoult J, Rouas-Freiss N, Carosella ED, Grosse-Wilde H: Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004. Hum Immunol. 2005 Aug;66(8):853-63.
PubMed
Le Rond S, Le Maoult J, Creput C, Menier C, Deschamps M, Le Friec G, Amiot L, Durrbach A, Dausset J, Carosella ED, Rouas-Freiss N: Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur J Immunol. 2004 Mar;34(3):649-60.
PubMed
Le Rond S, Gonzalez A, Gonzalez AS, Carosella ED, Rouas-Freiss N: Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways. Immunology. 2005 Nov; 116(3): 297-307.
PubMed
Lafon M, Prehaud C, Megret F, Lafage M, Mouillot G, Roa M, Moreau P, Rouas-Freiss N, Carosella ED: Modulation of HLA-G Expression in Human Neural Cells after Neurotropic Viral Infections. J Virol. 2005 Dec; 79(24): 15226-15237.
PubMed
Zhang X, Lin A, Han QY, Zhang JG, Chen QY, Ye YH, Zhou WJ, Xu HH, Gan J, Yan WH: Intratumor heterogeneity of HLA-G expression in cancer lesions. Front Immunol. 2020 Nov 19;11:565759.
PubMed
Swets M, Wouters A, Krijgsman D, van Vlierberghe RL, Boot A, van Eendenburg JD, van Wezel T, Gelderblom H, van de Velde CJ, van den Elsen PJ, Kuppen PJ: HLA-G protein expression in colorectal cancer evaluated by immunohistochemistry and Western blot analysis: Its expression characteristics remain enigmatic. Clin Immunol. 2018 Sep;194:80-86.
PubMed
Gonzalez A, Alegre E, Arroyo A, LeMaoult J, Echeveste JI: Identification of circulating nonclassic human leukocyte antigen G (HLA-G)-like molecules in exudates. Clin Chem. 2011 Jul;57(7):1013-22.
PubMed
Variant
0.1 mg
1B-431-C100
In stock
286.00 USD

0.025 mg
1B-431-C025
Delivery 1 week
143.00 USD
Variant
0.1 mg
1B-431-C100
In stock
286.00 USD

0.025 mg
1B-431-C025
Delivery 1 week
143.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
0.1 mg
165.00 USD